Latest News





08-03-15 Zogenix to Release Second Quarter 2015 Financial Results and Host Conference Call & Webcast on August 10
07-30-15 Zogenix Prices Public Offering of Common Stock
07-28-15 Zogenix Announces Proposed Public Offering of 3,800,000 Shares of Common Stock

  Relday is a proprietary, once-monthly subcutaneous formulation of risperidone for treating schizophrenia. The Relday Multi-Dose study was initiated in January and results are anticipated in Q3 2015.

  DosePro is a first-in-class, easy-to-use drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle. DosePro offers benefits to patients including instant, easy dosing, less anxiety over self-injection, no need for sharps disposal, no risk of needle stick injury or contamination, and reliable performance.